BACKGROUND AND OBJECTIVES: It is unknown how gestational age (GA) impacts neonatal morbidities in infants with critical congenital heart disease (CCHD). We aim to quantify GA-specific mortality and neonatal morbidity in infants with CCHD. METHODS: Cohort study using a database linking birth certificate, infant hospital discharge, readmission, and death records, including infants 22 to 42 weeks' GA without chromosomal anomalies (2005-2012, 2 988 925 live births). The International Classification of Diseases, Ninth Revision diagnostic and procedure codes were used to define CCHD and neonatal morbidities (intraventricular hemorrhage, retinopathy, periventricular leukomalacia, chronic lung disease, necrotizing enterocolitis). Adjusted absolute risk differences (ARDs) with 95% confidence intervals (CIs) were calculated. RESULTS: We identified 6903 out of 2 968 566 (0.23%) infants with CCHD. The incidence of CCHD was highest at 29 to 31 weeks' GA (0.9%) and lowest at 39 to 42 weeks (0.2%). Combined neonatal morbidity or mortality in infants with and without CCHD was 82.8% and 57.9% at <29 weeks and declined to 10.9% and 0.1% at 39 to 42 weeks' GA. In infants with CCHD, being born at 34 to 36 weeks was associated with a higher risk of death or morbidity than being born at 37 to 38 weeks (adjusted ARD 9.1%, 95% CI 5.5% to 12.7%), and being born at 37 to 38 weeks was associated with a higher risk of death or morbidity than 39 to 42 weeks (adjusted ARD 3.2%, 95% CI 1.6% to 4.9%). CONCLUSIONS: Infants born with CCHD are at high risk of neonatal morbidity. Morbidity remains increased across all GA groups in comparison with infants born at 39 to 42 weeks. This substantial risk of neonatal morbidity is important to consider when caring for this patient population.
BACKGROUND AND OBJECTIVES: It is unknown how gestational age (GA) impacts neonatal morbidities in infants with critical congenital heart disease (CCHD). We aim to quantify GA-specific mortality and neonatal morbidity in infants with CCHD. METHODS: Cohort study using a database linking birth certificate, infant hospital discharge, readmission, and death records, including infants 22 to 42 weeks' GA without chromosomal anomalies (2005-2012, 2 988 925 live births). The International Classification of Diseases, Ninth Revision diagnostic and procedure codes were used to define CCHD and neonatal morbidities (intraventricular hemorrhage, retinopathy, periventricular leukomalacia, chronic lung disease, necrotizing enterocolitis). Adjusted absolute risk differences (ARDs) with 95% confidence intervals (CIs) were calculated. RESULTS: We identified 6903 out of 2 968 566 (0.23%) infants with CCHD. The incidence of CCHD was highest at 29 to 31 weeks' GA (0.9%) and lowest at 39 to 42 weeks (0.2%). Combined neonatal morbidity or mortality in infants with and without CCHD was 82.8% and 57.9% at <29 weeks and declined to 10.9% and 0.1% at 39 to 42 weeks' GA. In infants with CCHD, being born at 34 to 36 weeks was associated with a higher risk of death or morbidity than being born at 37 to 38 weeks (adjusted ARD 9.1%, 95% CI 5.5% to 12.7%), and being born at 37 to 38 weeks was associated with a higher risk of death or morbidity than 39 to 42 weeks (adjusted ARD 3.2%, 95% CI 1.6% to 4.9%). CONCLUSIONS:Infants born with CCHD are at high risk of neonatal morbidity. Morbidity remains increased across all GA groups in comparison with infants born at 39 to 42 weeks. This substantial risk of neonatal morbidity is important to consider when caring for this patient population.
Authors: Daniel A Castellanos; Keila N Lopez; Jason L Salemi; Alireza A Shamshirsaz; Yunfei Wang; Shaine A Morris Journal: J Pediatr Date: 2020-07 Impact factor: 4.406
Authors: Young Mi Yoon; Seong Phil Bae; Yoon-Joo Kim; Jae Gun Kwak; Woong-Han Kim; Mi Kyoung Song; Seung Han Shin; Ee-Kyung Kim; Han-Suk Kim Journal: Clin Exp Pediatr Date: 2020-07-15
Authors: Fabio Savorgnan; Justin J Elhoff; Danielle Guffey; David Axelrod; Jason R Buckley; Michael Gaies; Nancy S Ghanayem; Javier J Lasa; Lara Shekerdemian; James S Tweddell; David K Werho; Justin Yeh; Martina A Steurer Journal: Ann Thorac Surg Date: 2020-10-17 Impact factor: 4.330
Authors: Ting Guo; Vann Chau; Shabnam Peyvandi; Beatrice Latal; Patrick S McQuillen; Walter Knirsch; Anne Synnes; Maria Feldmann; Nadja Naef; M Mallar Chakravarty; Alessandra De Petrillo; Emma G Duerden; A James Barkovich; Steven P Miller Journal: Neuroimage Date: 2018-06-15 Impact factor: 6.556
Authors: Sara C Handley; Molly Passarella; Tia T Raymond; Scott A Lorch; Anne Ades; Elizabeth E Foglia Journal: Resuscitation Date: 2021-06-06 Impact factor: 6.251
Authors: Martina A Steurer; Shabnam Peyvandi; Rebecca J Baer; Scott P Oltman; Christina D Chambers; Mary E Norton; Kelli K Ryckman; Anita J Moon-Grady; Roberta L Keller; Stephen C Shiboski; Laura L Jelliffe-Pawlowski Journal: J Am Heart Assoc Date: 2019-11-15 Impact factor: 5.501
Authors: Martina A Steurer; Rebecca J Baer; Edmund Burke; Shabnam Peyvandi; Scott Oltman; Christina D Chambers; Mary E Norton; Larry Rand; Satish Rajagopal; Kelli K Ryckman; Sky K Feuer; Liang Liang; Randi A Paynter; Molly McCarthy; Anita J Moon-Grady; Roberta L Keller; Laura L Jelliffe-Pawlowski Journal: J Am Heart Assoc Date: 2018-09-04 Impact factor: 5.501
Authors: Shabnam Peyvandi; Rebecca J Baer; Anita J Moon-Grady; Scott P Oltman; Christina D Chambers; Mary E Norton; Satish Rajagopal; Kelli K Ryckman; Laura L Jelliffe-Pawlowski; Martina A Steurer Journal: J Am Heart Assoc Date: 2018-10-16 Impact factor: 5.501
Authors: David Hodgson; Richard Pebody; Jasmina Panovska-Griffiths; Marc Baguelin; Katherine E Atkins Journal: BMC Med Date: 2020-11-18 Impact factor: 8.775